Multifocal myoclonus induced by haloperidol.

Area of Science:

• Neuroscience
• Geriatric Psychiatry
• Pharmacology

Background:

• Haloperidol is a commonly prescribed antipsychotic for managing behavioral and psychological symptoms of dementia, particularly agitation.
• However, its use is limited by a significant risk of adverse effects, impacting patient safety and quality of life.

Observation:

• A patient with severe Alzheimer's disease was initiated on haloperidol treatment for agitation.
• Shortly after the commencement of haloperidol therapy, the patient exhibited new-onset non-epileptic myoclonus.

Findings:

• This case represents the first documented instance of non-epileptic myoclonus directly linked to the initiation of haloperidol treatment in a patient with severe Alzheimer's disease.
• The observed myoclonus suggests a potential, previously unreported adverse reaction to haloperidol in this specific patient population.

Implications:

• This finding highlights the need for careful monitoring of patients with Alzheimer's disease receiving haloperidol, especially for new neurological symptoms.
• Further research is warranted to investigate the potential causal link between haloperidol and non-epileptic myoclonus in dementia patients.
• Clinicians should consider alternative or adjunctive treatments for agitation in dementia to mitigate the risk of such adverse events.